News Feature | November 18, 2026

A Validated Target Is No Longer A De-Risked Program

Source: Drug Discovery Online

By Morgan Kohler, Executive Editor

BioScience Antibody,T-Cell,Antibodies cell,Molecule of immunoglobulin G antibody-GettyImages-2208445482

Four groups are now developing degraders against the same immunology target, and none of them can differentiate on the biology.

Insilico Medicine, a generative AI drug discovery company, nominated ISM9546, an oral VAV1 degrader, as a preclinical candidate on Oct. 13, developed for inflammatory bowel disease and rheumatoid arthritis first. Founder and co-CEO Alex Zhavoronkov described VAV1 as sitting at “a choke point of adaptive immunity.” It is the company’s 35th preclinical candidate since 2021 and its 11th in the first 10 months of 2026 alone.

Insilico is entering a field in which Monte Rosa Therapeutics is leading. Monte Rosa, in collaboration with Novartis, announced that MRT-6160 — a selective, orally bioavailable VAV1 degrader — entered Phase 2 in September 2026. Hengrui Pharmaceuticals reported VAV1 degradation inducers in June 2026. Haisco Pharmaceutical Group disclosed cereblon-binding VAV1 degraders the same month. Insilico’s own filings in the class surfaced in August.

VAV1 is a 95 kDa guanine nucleotide exchange factor and a positive regulator of T-cell and B-cell receptor signaling, with expression normally restricted to hematopoietic cells. Restricted expression plus a signaling choke point is close to an ideal immunology target profile, which is why it attracted four programs.

With the biology settled and shared, the competitive argument has moved somewhere else: to where the molecule goes in the body.

What This Means For Drug Discovery

Insilico’s differentiation case rests on peripheral restriction, and the company reported establishing it two ways. The first is MDCKII-MDR1 assays, which indicate whether the efflux transporter at the blood-brain barrier clears the molecule. The second is in vivo tissue distribution studies showing low brain exposure. Together they support a claim that the degrader acts on peripheral immune signaling without meaningful CNS penetration, which is a safety argument that matters for a target embedded in receptor signaling.

Zhavoronkov was careful about what that establishes: “These are preclinical results, and human studies will show whether they translate.” The caution is warranted. Peripheral restriction demonstrated in MDCKII-MDR1 and rodent distribution has a mixed record of predicting human brain exposure.

What this pattern should change is how discovery organizations treat the phrase “validated target” in portfolio review. The conventional logic holds that strong human genetic and functional support de-risks a program. That logic breaks down when the support is public. By the time a target’s evidence base is strong enough to justify one program, it is strong enough to justify four, and everyone is reading the same literature and the same filings. Biological validation moves out of a single company’s risk column and into everyone’s, and what remains is a chemistry and property race.

That has a direct consequence for how programs get specified. On a contested target, peripheral restriction, half-life, and selectivity specifications can no longer be decided after target selection, because they are the only remaining differentiators and they determine chemistry strategy from the first series. Target selection and molecular property targets have to be a single decision rather than sequential ones.

It also changes who needs to be in the room during lead optimization. If brain exposure is the differentiator, the assays establishing it are differentiation assays rather than routine absorption, distribution, metabolism, and excretion (ADME), and they warrant resourcing on that basis. Drug metabolism and pharmacokinetics (DMPK), safety pharmacology, and competitive intelligence belong in the same conversation well before candidate selection.

Hengrui and Haisco filed patents in June, and Insilico filed in August with an October nomination. Filing trackers such as BioWorld Science surfaced these patent filings. Most organizations run that kind of monitoring inside competitive intelligence reviews that happen on a quarterly cadence, well downstream of the point where a target gets picked.

There is a broader signal here about generative chemistry platforms. They are demonstrably good at reaching validated targets quickly, which means the advantage they confer shows up in property optimization rather than target novelty. For a company whose pipeline strategy assumes that an AI platform will find differentiated targets, this is worth sitting with. The platform may instead be efficient at arriving where three competitors already are.

And where a program’s differentiation ultimately rests on a property claim such as CNS exclusion, it is worth defining in advance what clinical evidence would confirm or refute it. That claim is what the eventual deal value rests on.

The Discovery Question

How would your team have known, six months earlier, that three other groups had already filed?

Related Drug Discovery Online Editorials

About The Editor

Morgan Kohler is the executive editor of guest expert articles for Drug Discovery Online, working with industry experts to develop insightful and informative pieces about drug discovery and preclinical drug development science, regulatory strategy, trends, analyses, and commentary.

Morgan holds a master’s degree in professional writing and web content development and has worked in the publishing industry since 2018. Before working for Drug Discovery Online, she guided and edited industry-expert-bylined content on topics related to radiology and economics.